Jupiter Neurosciences, Inc.
JUNS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001679628
No open-market purchases or sales by Jupiter Neurosciences, Inc. insiders were filed in the last 90 days; 13 institutions reported holding it in 13F filings for Q2 2026, worth $826.9K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Jupiter Neurosciences, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- +3 vs. Q1 2026
- Shares held
- 1.25M
- −650.7K (−34.2%) vs. Q1 2026
- Total value
- $826.9K
- +$110.7K (+15.5%) vs. Q1 2026
- New holders
- 6
- 1 more added
- Sold out
- 3
- 4 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting JUNS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $826.9K |
| Q1 2026 | 10 | $716.1K |
| Q4 2025 | 12 | $1.64M |
| Q3 2025 | 9 | $2.39M |
| Q2 2025 | 2 | $66.3K |
| Q1 2025 | 7 | $230.5K |
| Q4 2024 | 3 | $54.3K |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Jupiter Neurosciences, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vestor Capital, LLC | 2,193 | $557.0K | 0.03% | −968,792−99.8% | Reduced |
| Jane Street Group, LLC | 533,395 | $114.3K | 0.00% | +533,395 | New |
| Virtu Financial LLC | 231,240 | $50.0K | 0.00% | +217,665+1,603.4% | Added |
| Geode Capital Management, LLC | 156,127 | $33.4K | 0.00% | −55,569−26.2% | Reduced |
| Vanguard Capital Management LLC | 128,042 | $27.4K | 0.00% | −231,869−64.4% | Reduced |
| Vanguard Fiduciary Trust Co | 84,173 | $18.0K | 0.00% | −3,616−4.1% | Reduced |
| XTX Topco Ltd | 32,770 | $7.02K | 0.00% | +32,770 | New |
| Tower Research Capital LLC (TRC) | 28,786 | $6.17K | 0.00% | +28,786 | New |
| StoneX Group Inc. | 20,602 | $5.68K | 0.00% | +20,602 | New |
| Northern Trust Corp | 25,346 | $5.43K | 0.00% | 00.0% | Unchanged |
| Level Four Advisory Services, LLC | 10,000 | $2.14K | 0.00% | +10,000 | New |
| MidFirst Bank | 1,000 | $214 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 546 | $117 | 0.00% | +546 | New |
| Yorkville Advisors Global, LP | 0 | $0 | 0.00% | −129,000−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −101,661−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −3,928−100.0% | Sold out |